Marshall Wace LLP Makes New $554,000 Investment in Disc Medicine, Inc. (NASDAQ:IRON)

Marshall Wace LLP acquired a new position in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 12,300 shares of the company's stock, valued at approximately $554,000.

A number of other institutional investors and hedge funds have also bought and sold shares of IRON. Frazier Life Sciences Management L.P. increased its stake in Disc Medicine by 19.8% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 785,000 shares of the company's stock valued at $45,342,000 after acquiring an additional 130,000 shares during the period. Parkman Healthcare Partners LLC increased its position in shares of Disc Medicine by 78.4% during the fourth quarter. Parkman Healthcare Partners LLC now owns 92,871 shares of the company's stock valued at $5,364,000 after purchasing an additional 40,813 shares during the period. Perceptive Advisors LLC raised its stake in shares of Disc Medicine by 14.2% in the fourth quarter. Perceptive Advisors LLC now owns 1,023,045 shares of the company's stock valued at $59,091,000 after purchasing an additional 127,404 shares in the last quarter. Virtu Financial LLC bought a new position in Disc Medicine in the fourth quarter worth $797,000. Finally, Wellington Management Group LLP boosted its stake in Disc Medicine by 224.6% during the fourth quarter. Wellington Management Group LLP now owns 177,726 shares of the company's stock worth $10,265,000 after buying an additional 122,981 shares in the last quarter. Institutional investors own 83.70% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. BMO Capital Markets reaffirmed an "outperform" rating and set a $70.00 price objective (up from $50.00) on shares of Disc Medicine in a report on Monday, June 17th. HC Wainwright restated a "buy" rating and set a $70.00 price target on shares of Disc Medicine in a research note on Monday, September 16th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $85.00 price objective on shares of Disc Medicine in a research note on Friday, September 20th. Wedbush restated an "outperform" rating and set a $57.00 target price on shares of Disc Medicine in a research report on Friday, August 9th. Finally, Wells Fargo & Company began coverage on Disc Medicine in a research report on Thursday, August 22nd. They issued an "overweight" rating and a $75.00 price target on the stock. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $64.13.

Disc Medicine Price Performance

Shares of IRON stock traded up $0.70 during trading hours on Thursday, hitting $47.47. 145,922 shares of the company's stock were exchanged, compared to its average volume of 346,851. Disc Medicine, Inc. has a 52 week low of $25.60 and a 52 week high of $77.60. The stock has a market cap of $1.17 billion, a price-to-earnings ratio of -13.84 and a beta of 0.59. The stock's 50-day moving average is $47.91 and its 200-day moving average is $41.74.

Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($1.03) EPS for the quarter, topping analysts' consensus estimates of ($1.11) by $0.08. Equities research analysts forecast that Disc Medicine, Inc. will post -4.19 earnings per share for the current fiscal year.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.